| MeSH term | MeSH ID | Detail |
|---|---|---|
| Breast Neoplasms | D001943 | 24 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Pancreatic Neoplasms | D010190 | 77 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Mammary Neoplasms, Experimental | D008325 | 67 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Prostatic Neoplasms | D011471 | 126 associated lipids |
| Melanoma | D008545 | 69 associated lipids |
| Brain Diseases | D001927 | 27 associated lipids |
| Leukemia P388 | D007941 | 43 associated lipids |
MAYTANSINE
MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.
Cross Reference
Introduction
To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with MAYTANSINE?
MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with MAYTANSINE
PubChem Associated disorders and diseases
What pathways are associated with MAYTANSINE
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with MAYTANSINE?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with MAYTANSINE?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with MAYTANSINE?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with MAYTANSINE?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with MAYTANSINE?
Xenograft Model
Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with MAYTANSINE
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Salomon PL and Singh R | Sensitive ELISA Method for the Measurement of Catabolites of Antibody-Drug Conjugates (ADCs) in Target Cancer Cells. | 2015 | Mol. Pharm. | pmid:25738394 |
| Mustacchi G et al. | HER2-positive metastatic breast cancer: a changing scenario. | 2015 | Crit. Rev. Oncol. Hematol. | pmid:25748080 |
| Muzaffar M et al. | Acute Pancreatitis Associated With Ado-Trastuzumab Emtansine. | Am J Ther | pmid:25756468 | |
| Nguyen-Ngoc T and Raymond E | Reinvention of chemotherapy: drug conjugates and nanoparticles. | 2015 | Curr Opin Oncol | pmid:25783982 |
| Weiler D et al. | Rapid response to trastuzumab emtansine in a patient with HER2-driven lung cancer. | 2015 | J Thorac Oncol | pmid:25789838 |
| Guerin M et al. | [Trastuzumab emtansine (Kadcyla(®)) approval in HER2-positive metastatic breast cancers]. | 2015 | Bull Cancer | pmid:25790739 |
| Niell HB et al. | Effect of concentration and time of drug exposure on clonal growth of murine bladder cancer. | 1985 | Urology | pmid:2579500 |
| Widdison W et al. | Metabolites of antibody-maytansinoid conjugates: characteristics and in vitro potencies. | 2015 | Mol. Pharm. | pmid:25826705 |
| Hong EE et al. | Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation. | 2015 | Mol. Pharm. | pmid:25856201 |
| Van den Mooter T et al. | Trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer. | 2015 | Expert Opin Biol Ther | pmid:25865453 |
| Sibaud V et al. | T-DM1 extravasation: first description. | 2016 | J Eur Acad Dermatol Venereol | pmid:25879278 |
| Ab O et al. | IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors. | 2015 | Mol. Cancer Ther. | pmid:25904506 |
| Hamblett KJ et al. | AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma. | 2015 | Mol. Cancer Ther. | pmid:25931519 |
| Dholaria B and Srinivasan S | T-DM1-related carotenoderma and hand-foot syndrome. | 2015 | Lancet | pmid:25933279 |
| Kan S et al. | Gemcitabine treatment enhances HER2 expression in low HER2-expressing breast cancer cells and enhances the antitumor effects of trastuzumab emtansine. | 2015 | Oncol. Rep. | pmid:25976081 |
| Esteva FJ et al. | What Can We Learn about Antibody-Drug Conjugates from the T-DM1 Experience? | 2015 | Am Soc Clin Oncol Educ Book | pmid:25993162 |
| Miranda Romero P and MarÃn Gil R | Trastuzumab emtansine in locally advanced or metastatic HER2 positive breast cancer; GENESIS-SEFH drug evaluation report. | 2015 | Farm Hosp | pmid:26005893 |
| Shen BQ et al. | Non-Clinical Disposition and Metabolism of DM1, a Component of Trastuzumab Emtansine (T-DM1), in Sprague Dawley Rats. | 2015 | Drug Metab Lett | pmid:26031461 |
| Hayashi T et al. | Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer. | 2015 | J. Urol. | pmid:26047983 |
| van Geel R et al. | Chemoenzymatic Conjugation of Toxic Payloads to the Globally Conserved N-Glycan of Native mAbs Provides Homogeneous and Highly Efficacious Antibody-Drug Conjugates. | 2015 | Bioconjug. Chem. | pmid:26061183 |
| Piwko C et al. | Safety Profile and Costs of Related Adverse Events of Trastuzumab Emtansine for the Treatment of HER2-Positive Locally Advanced or Metastatic Breast Cancer Compared to Capecitabine Plus Lapatinib from the Perspective of the Canadian Health-Care System. | 2015 | Clin Drug Investig | pmid:26123628 |
| Beerli RR et al. | Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency. | 2015 | PLoS ONE | pmid:26132162 |
| Chung YC et al. | Caveolin-1 Dependent Endocytosis Enhances the Chemosensitivity of HER-2 Positive Breast Cancer Cells to Trastuzumab Emtansine (T-DM1). | 2015 | PLoS ONE | pmid:26172389 |
| Nguyen M et al. | Preclinical Efficacy and Safety Assessment of an Antibody-Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma. | 2015 | Clin. Cancer Res. | pmid:26240273 |
| Michel LL et al. | T-DM1 as a New Treatment Option for Patients with Metastatic HER2-positive Breast Cancer in Clinical Practice. | 2015 | Anticancer Res. | pmid:26254411 |
| Storz U | Antibody-drug conjugates: Intellectual property considerations. | 2015 | MAbs | pmid:26292154 |
| Gébleux R et al. | Antibody Format and Drug Release Rate Determine the Therapeutic Activity of Noninternalizing Antibody-Drug Conjugates. | 2015 | Mol. Cancer Ther. | pmid:26294742 |
| Bartsch R et al. | Activity of T-DM1 in Her2-positive breast cancer brain metastases. | 2015 | Clin. Exp. Metastasis | pmid:26303828 |
| MartÃnez MT et al. | Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature. | 2016 | Crit. Rev. Oncol. Hematol. | pmid:26318092 |
| Montero JC et al. | Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling. | 2015 | Oncotarget | pmid:26336133 |
| Cosmai L et al. | Renal toxicity of anticancer agents targeting HER2 and EGFR. | 2015 | J. Nephrol. | pmid:26341657 |
| Widdison WC et al. | Development of Anilino-Maytansinoid ADCs that Efficiently Release Cytotoxic Metabolites in Cancer Cells and Induce High Levels of Bystander Killing. | 2015 | Bioconjug. Chem. | pmid:26355774 |
| Yardley DA et al. | Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study. | Cancer J | pmid:26389758 | |
| Kan S et al. | Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells. | 2015 | BMC Cancer | pmid:26475267 |
| Zhang YG et al. | Nocardiopsis ansamitocini sp. nov., a new producer of ansamitocin P-3 of the genus Nocardiopsis. | 2016 | Int. J. Syst. Evol. Microbiol. | pmid:26486850 |
| Askoxylakis V et al. | Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment. | 2016 | J. Natl. Cancer Inst. | pmid:26547932 |
| Roviello G et al. | Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives. | 2016 | Tumour Biol. | pmid:26566626 |
| Li S et al. | Constitutive overexpression of asm18 increases the production and diversity of maytansinoids in Actinosynnema pretiosum. | 2016 | Appl. Microbiol. Biotechnol. | pmid:26572523 |
| Eisenstein M | Medicine: Eyes on the target. | 2015 | Nature | pmid:26580159 |
| Fan Y et al. | Enhancement of UDPG synthetic pathway improves ansamitocin production in Actinosynnem pretiosum. | 2016 | Appl. Microbiol. Biotechnol. | pmid:26585444 |
| Gebhart G et al. | Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. | 2016 | Ann. Oncol. | pmid:26598545 |
| Müller P et al. | Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. | 2015 | Sci Transl Med | pmid:26606967 |
| Luo Q et al. | Structural Characterization of a Monoclonal Antibody-Maytansinoid Immunoconjugate. | 2016 | Anal. Chem. | pmid:26629796 |
| Hamblett KJ et al. | SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm. | 2015 | Cancer Res. | pmid:26631267 |
| Singh JC and Lichtman SM | Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients. | 2015 | Drugs Aging | pmid:26645293 |
| T-DM1 Extends Survival in HER2+ Breast Cancer. | 2016 | Cancer Discov | pmid:26676162 | |
| Checkpoint Inhibitors Boost Power of Antibody-Drug Conjugate. | 2016 | Cancer Discov | pmid:26701087 | |
| Elsada A et al. | NICE guidance on trastuzumab emtansine for HER2-positive advanced breast cancer. | 2016 | Lancet Oncol. | pmid:26703893 |
| Yan H et al. | Ado-Trastuzumab Emtansine Targets Hepatocytes Via Human Epidermal Growth Factor Receptor 2 to Induce Hepatotoxicity. | 2016 | Mol. Cancer Ther. | pmid:26712117 |
| de Vries CL et al. | Response of symptomatic brain metastases from HER-2 overexpressing breast cancer with T-DM1. | 2016 | J. Neurooncol. | pmid:26732082 |
| Catcott KC et al. | Microscale screening of antibody libraries as maytansinoid antibody-drug conjugates. | 2016 | MAbs | pmid:26752675 |
| Li JY et al. | A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy. | 2016 | Cancer Cell | pmid:26766593 |
| Heudi O et al. | Quantitative analysis of maytansinoid (DM1) in human serum by on-line solid phase extraction coupled with liquid chromatography tandem mass spectrometry - Method validation and its application to clinical samples. | 2016 | J Pharm Biomed Anal | pmid:26771131 |
| Kantarjian HM et al. | A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. | 2016 | Clin Lymphoma Myeloma Leuk | pmid:26775883 |
| Jerjian TV et al. | Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy. | 2016 | Pharmacotherapy | pmid:26799352 |
| Yabe N et al. | [A Case of Advanced Breast Cancer in Which Marked Improvement of Joint Pain Was Obtained with Stepwise Dose Reduction of Trastuzumab Emtansine (T-DM1)]. | 2015 | Gan To Kagaku Ryoho | pmid:26805183 |
| Raja SM et al. | Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition. | 2016 | Oncotarget | pmid:26859680 |
| Squires H et al. | Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. | 2016 | Pharmacoeconomics | pmid:26892972 |
| Vankemmelbeke M and Durrant L | Third-generation antibody drug conjugates for cancer therapy--a balancing act. | 2016 | Ther Deliv | pmid:26893243 |
| Maass KF et al. | Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design. | 2016 | AAPS J | pmid:26912181 |
| Kashiwaba M et al. | A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer. | 2016 | Jpn. J. Clin. Oncol. | pmid:26917603 |
| Baselga J et al. | Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer. | 2016 | Clin. Cancer Res. | pmid:26920887 |
| Dillon RL et al. | Trastuzumab-deBouganin Conjugate Overcomes Multiple Mechanisms of T-DM1 Drug Resistance. | 2016 | J. Immunother. | pmid:26938945 |
| Shah MH et al. | Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors. | 2016 | Invest New Drugs | pmid:26961907 |
| de Goeij BE and Lambert JM | New developments for antibody-drug conjugate-based therapeutic approaches. | 2016 | Curr. Opin. Immunol. | pmid:26963132 |
| Lanshoeft C et al. | Analysis of small molecule antibody-drug conjugate catabolites in rat liver and tumor tissue by liquid extraction surface analysis micro-capillary liquid chromatography/tandem mass spectrometry. | 2016 | Rapid Commun. Mass Spectrom. | pmid:26969923 |
| Krop IE et al. | Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer. | 2016 | Breast Cancer Res. | pmid:26979312 |
| Shen K et al. | Safety and Efficacy of Trastuzumab Emtansine in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: a Meta-analysis. | 2016 | Sci Rep | pmid:26979925 |
| Frenel JS et al. | [Trastuzumab emtansine in the systemic treatment of HER-2-positive breast cancer brain metastases]. | 2016 | Bull Cancer | pmid:26992855 |
| Coiffier B et al. | A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. | 2016 | Br. J. Haematol. | pmid:27010483 |
| Ogitani Y et al. | DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. | 2016 | Clin. Cancer Res. | pmid:27026201 |
| Singh AP et al. | Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1). | 2016 | AAPS J | pmid:27029797 |
| Martin M et al. | Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study. | 2016 | Ann. Oncol. | pmid:27052654 |
| Kwon Y et al. | Telangiectasia and Pulmonary Arterial Hypertension Following Treatment With Trastuzumab Emtansine: A Case Report. | 2016 | Chest | pmid:27055712 |
| T-DM1 Combo Graduates from I-SPY 2. | 2016 | Cancer Discov | pmid:27095360 | |
| Feng L et al. | Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer. | 2016 | J. Exp. Clin. Cancer Res. | pmid:27102688 |
| Walles M et al. | New Insights in Tissue Distribution, Metabolism, and Excretion of [3H]-Labeled Antibody Maytansinoid Conjugates in Female Tumor-Bearing Nude Rats. | 2016 | Drug Metab. Dispos. | pmid:27122302 |
| Tsuda M et al. | Abnormal Corneal Lesions Induced by Trastuzumab Emtansine: An Antibody-Drug Conjugate for Breast Cancer. | 2016 | Cornea | pmid:27149538 |
| Sandra K et al. | Multiple heart-cutting and comprehensive two-dimensional liquid chromatography hyphenated to mass spectrometry for the characterization of the antibody-drug conjugate ado-trastuzumab emtansine. | 2016 | J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. | pmid:27160547 |
| Ogitani Y et al. | Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. | 2016 | Cancer Sci. | pmid:27166974 |
| Jacot W et al. | Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases. | 2016 | Breast Cancer Res. Treat. | pmid:27167986 |
| Fan Y et al. | Effects of modulation of pentose-phosphate pathway on biosynthesis of ansamitocins in Actinosynnema pretiosum. | 2016 | J. Biotechnol. | pmid:27173582 |
| Ponte JF et al. | Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody-Maytansinoid Conjugates. | 2016 | Bioconjug. Chem. | pmid:27174129 |
| Bellat V et al. | Smart Nanotransformers with Unique Enzyme-Inducible Structural Changes and Drug Release Properties. | 2016 | Biomacromolecules | pmid:27180972 |
| Singh R et al. | A New Triglycyl Peptide Linker for Antibody-Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells. | 2016 | Mol. Cancer Ther. | pmid:27197308 |
| Hamblett KJ et al. | Altering Antibody-Drug Conjugate Binding to the Neonatal Fc Receptor Impacts Efficacy and Tolerability. | 2016 | Mol. Pharm. | pmid:27248573 |
| Martin M and López-Tarruella S | Emerging Therapeutic Options for HER2-Positive Breast Cancer. | 2016 | Am Soc Clin Oncol Educ Book | pmid:27249772 |
| Wang C et al. | Chromatography-based methods for determining molar extinction coefficients of cytotoxic payload drugs and drug antibody ratios of antibody drug conjugates. | 2016 | J Chromatogr A | pmid:27286648 |
| Cilliers C et al. | Multiscale Modeling of Antibody-Drug Conjugates: Connecting Tissue and Cellular Distribution to Whole Animal Pharmacokinetics and Potential Implications for Efficacy. | 2016 | AAPS J | pmid:27287046 |
| Dzimitrowicz H et al. | T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab. | 2016 | J. Clin. Oncol. | pmid:27298406 |
| Géraud A et al. | Preliminary results of the concurrent use of radiotherapy for bone metastases and trastuzumab emtansine in patients with HER2-positive metastatic breast cancer. | 2016 | Cancer Radiother | pmid:27342941 |
| Ludueña RF et al. | The interaction of phomopsin A with bovine brain tubulin. | 1989 | Arch. Biochem. Biophys. | pmid:2735765 |
| Mitsuya K et al. | Expansive hematoma in delayed cerebral radiation necrosis in patients treated with T-DM1: a report of two cases. | 2016 | BMC Cancer | pmid:27377061 |
| Chen L et al. | In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate. | 2016 | MAbs | pmid:27380163 |
| Li C et al. | Ethnic sensitivity assessment of the antibody-drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer. | 2016 | Cancer Chemother. Pharmacol. | pmid:27423671 |
| Kim SB et al. | Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer. | 2016 | Int. J. Cancer | pmid:27428671 |
| Mahtani RL and Vogel CL | When Can a Salvage Therapy (T-DM1) Take the Lead? | 2016 | J. Clin. Oncol. | pmid:27432926 |
| Chen Y et al. | Structural Characterization of Cross-Linked Species in Trastuzumab Emtansine (Kadcyla). | 2016 | Bioconjug. Chem. | pmid:27458087 |
| Ohashi K et al. | Trastuzumab Emtansine in HER2+ Recurrent Metastatic Non-Small-Cell Lung Cancer: Study Protocol. | 2017 | Clin Lung Cancer | pmid:27497829 |
| Eckelmann D et al. | Occurrence and spatial distribution of maytansinoids in Putterlickia pyracantha, an unexplored resource of anticancer compounds. | 2016 | Fitoterapia | pmid:27521896 |